Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) today announced that the Company will report its financial results for the first quarter 2015, on Tuesday, May 12, 2015 prior to a conference call with the investment community, scheduled at 8:30 a.m. EDT.
Investors and the public are invited to access the live audio webcast through the link below. Participants who would like to ask questions during the question and answer session must participate by telephone also. Participants are encouraged to log-in and/or dial-in fifteen minutes before the conference call begins. The webcast replay is expected to be available on our investor website, http://ir.navidea.com, approximately two to four hours after the live event.
Event: | Navidea Biopharmaceuticals Q1 2015 Financial Results Conference Call | |||
Date/Time: | Tuesday, May 12, 2015 at 8:30 a.m. EDT | |||
Webcast Link: | ||||
Dial-in Number – US: | 1 (855) 897-5884 | |||
Dial in Number – Int’l: | 1 (720) 634-2940 | |||
Confirmation Number: | 39734236 | |||
Replay: | A webcast replay will be available on the Investor Relations section of our website at http://ir.navidea.com for 30 days. | |||
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE MKT:
NAVB) is a biopharmaceutical company focused on the development and
commercialization of precision diagnostics, therapeutics and
radiopharmaceutical agents. Navidea is developing multiple
precision-targeted products and platforms including Manocept™ and
NAV4694 to help identify the sites and pathways of undetected disease
and enable better diagnostic accuracy, clinical decision-making,
targeted treatment and, ultimately, patient care. Lymphoseek®
(technetium Tc 99m tilmanocept) injection, Navidea’s first commercial
product from the Manocept platform, was approved by the FDA in March
2013 and in Europe in November 2014. Navidea’s strategy is to deliver
superior growth and shareholder return by bringing to market novel
radiopharmaceutical agents and therapeutics, and advancing the Company’s
pipeline through global partnering and commercialization efforts. For
more information, please visit www.navidea.com.
Contacts:
Investors
Tom
Baker, 617-532-0624
tbaker@navidea.com
or
Media
Sharon
Correia, 978-655-2686
Associate Director, Corporate Communications